Mesenchymal Stem Cells Derived Exosomes in Osteoarthritis Patients

Launched by ISFAHAN UNIVERSITY OF MEDICAL SCIENCES · Jun 14, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring a new treatment for knee osteoarthritis, a condition that causes pain and damage to the joints. Researchers are looking at tiny particles called exosomes, which come from special cells known as mesenchymal stem cells (MSCs). These exosomes may help reduce inflammation and support joint health by carrying important molecules that can improve how joint cells behave. The goal of the study is to find out if these exosomes can slow down or even help reverse the damage caused by osteoarthritis.

To participate in this trial, you may be eligible if you have been experiencing knee pain for at least three months, have a body mass index (BMI) between 21.5 and 29.5, and have been diagnosed with mild to moderate osteoarthritis in your knees. However, certain conditions like rheumatoid arthritis, severe joint deformities, or serious health issues could prevent you from joining. If you take part in the study, you can expect to receive treatment with these MSC-derived exosomes and be monitored for how it affects your knee pain and overall joint function. This research could lead to more effective treatments for osteoarthritis in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Chronic history (for at least 3 months) of knee joint pain
• • Body mass index (BMI) between 21.5 and 29.5
• • Radiographically documented knee osteoarthritis of grades 1 to 3 (Kellgren-Lawrence (K-L) radiographic classification scale)
• Exclusion Criteria:
• • Rheumatoid arthritis and other rheumatic diseases
• • Varus or valgus more than 10 degrees; lateral subluxation of the patella
• • Deformity at the joint levels or adjacent to the knee due to fracture or any other injury
• • Complete rupture of the ligament and meniscus leading to laxity or locking
• • Serious systemic, oncohematological, autoimmune diseases; history of severe allergy; serious failure of vital organs, inability to walk
• • Hyaluronic acid infiltration within the previous six months
• • Hemoglobin levels \<10 g/dL;